铂是卵巢癌全身治疗的关键组成部分。然而，大多数患者最终将面临复发，导致化疗耐药，尤其是对铂类药物的耐药。对于铂类耐药卵巢癌（PROC）患者来说，治疗选择有限，而且生存前景严峻。抗体药物偶联物 (ADC) 的出现有望成为 PROC 的未来治疗方法。本综述综合了当前有关 ADC 治疗 PROC 有效性的研究。它概括了针对特定抗原（例如叶酸受体 α (FRα)、MUC16、NaPi2b、间皮素、二肽酶 3 (DPEP3) 和人表皮生长因子受体 2 (HER2)）以及组织的新型 ADC 的进展和临床试验。因素，强调其潜在的抗肿瘤功效并与其他疗法联合使用。卵巢癌治疗中的 ADC 前景正在迅速发展，有望提供更有效的治疗途径。© 2024。作者。

Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospects are grim. The emergence of antibody-drug conjugates (ADCs) shows promises as a future treatment for PROC. This review synthesizes current research on the effectiveness of ADCs in treating PROC. It encapsulates the advancements and clinical trials of novel ADCs that target specific antigens such as Folate Receptor alpha (FRα), MUC16, NaPi2b, Mesothelin, Dipeptidase 3(DPEP3), and human epidermal growth factor receptor 2 (HER2), as well as tissue factor, highlighting their potential anti-tumor efficacy and used in combination with other therapies. The ADCs landscape in ovarian cancer therapeutics is swiftly evolving, promising more potent and efficacious treatment avenues.© 2024. The Author(s).